scholarly journals Pediatric pharmaceutical care with anti-infective medication in a patient with acute hematogenous osteomyelitis caused by methicillin-resistant Staphylococcus aureus

2020 ◽  
Vol 34 ◽  
pp. 205873842092571
Author(s):  
Chanmei Lv ◽  
Jiantao Lv ◽  
Yue Liu ◽  
Qifeng Liu ◽  
Dongna Zou
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
First Line ◽  
Methicillin Resistant ◽  
First Report ◽  
First Line Therapy ◽  
Acute Hematogenous Osteomyelitis ◽  
Serious Infections ◽  
Daily Dose ◽  
Red Man Syndrome

The infection of the bone marrow system caused by methicillin-resistant Staphylococcus aureus (MRSA) leads to a variety of common diseases which usually occur in children under the age of 12. Vancomycin (VCM) is the first-line therapy for MRSA-caused serious infections such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin and soft-tissue infection (e.g. necrotizing fasciitis) with a recommended dosage of 15–20 μg/mL. In this study, we first report a case of a child with MRSA-caused osteomyelitis who was successfully cured by VCM at a concentration of 4.86 μg/mL. VCM’s clinical daily dose of more than 4 g was of concern in light of recent evidence suggesting the increased risks of nephrotoxicity and red man syndrome when Cmin ⩾15 μg/mL and doses ⩾10 mg/kg in children. As far as we know, this is the first report on the lower dose of VCM in children with MRSA osteomyelitis.

scholarly journals Glycopeptide Intermediate Resistant Staphylococcus aureus (GISA) death in Scotland

2002 ◽  
Vol 6 (51) ◽  
Author(s):  
S Dancer
Keyword(s):  
Staphylococcus Aureus ◽  
United Kingdom ◽  
Laboratory Tests ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
First Line ◽  
Methicillin Resistant ◽  
First Report ◽  
The United Kingdom

Laboratory tests have confirmed that a patient who died last week in a hospital in, Lanarkshire, Scotland, was infected with a Glycopeptide Intermediate Resistant Staphylococcus aureus (GISA) (1). GISA has increased resistance to first line antibiotics used for treating infections caused by methicillin resistant Staphylococcus aureus (MRSA), namely, vancomycin and teicoplanin (2). This is the second report of an infection with this organism for Scotland, and possibly the first report in the United Kingdom of an associated death. (3).

scholarly journals Severe vancomycin-induced anaphylactic reaction

Medicina ◽  
2010 ◽  
Vol 46 (1) ◽  
pp. 31
Author(s):  
Rūta Kupstaitė ◽  
Asta Baranauskaitė ◽  
Margarita Pileckytė ◽  
Audrius Sveikata ◽  
Edmundas Kaduševičius ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Adverse Effects ◽  
Anaphylactic Reaction ◽  
Anaphylactoid Reaction ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Hypersensitivity Reactions ◽  
Blood Disorders ◽  
Methicillin Resistant ◽  
Aureus Infection ◽  
Red Man Syndrome

Vancomycin is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions – an anaphylactoid reaction known as “red man syndrome” and anaphylaxis. We report a case of a 23-year-old man who developed a vancomycin-induced anaphylactic reaction in the treatment of methicillin-resistant Staphylococcus aureus infection.

scholarly journals First report of sasX-positive methicillin-resistant Staphylococcus aureus in Japan

2017 ◽  
Vol 364 (16) ◽  
Author(s):  
Hidemasa Nakaminami ◽  
Teruyo Ito ◽  
Xiao Han ◽  
Ayumu Ito ◽  
Miki Matsuo ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Methicillin Resistant ◽  
First Report

scholarly journals Vancomycin-Associated Leukocytoclastic Vasculitis

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Makhawadee Pongruangporn ◽  
David J. Ritchie ◽  
Dongsi Lu ◽  
Jonas Marschall
Keyword(s):  
Staphylococcus Aureus ◽  
Skin Biopsy ◽  
Drug Administration ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Leukocytoclastic Vasculitis ◽  
Food And Drug Administration ◽  
Lower Extremities ◽  
Methicillin Resistant ◽  
Palpable Purpura ◽  
Serious Infections

Vancomycin is U.S. Food and Drug Administration (FDA) approved for treatment of serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or in individuals who have failed, cannot tolerate, or are allergic to other antibiotics. Very few cases of vancomycin-associated leukocytoclastic vasculitis have been published. We report on a patient who developed pruritus and palpable purpura in both lower extremities after receiving six days of intravenous vancomycin. Skin biopsy revealed leukocytoclastic vasculitis.

First report of a livestock‐associated methicillin‐resistant Staphylococcus aureus ST126 harbouring the mecC variant in Brazil

2020 ◽  
Author(s):  
José Givanildo Silva ◽  
Wydemberg José Araujo ◽  
Elma Lima Leite ◽  
Larissa Maranhão Dias ◽  
Priscylla Carvalho Vasconcelos ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Methicillin Resistant ◽  
First Report
Sign in / Sign up

Export Citation Format

Share Document